Department of  Neurosurgery
Menu  -
Call Us: (314) 362-3577

Gavin P. Dunn, MD, PhD

Gavin Dunn, MD, PhD

Associate Professor of Neurological Surgery, Neurology and Pathology/Immunology
Neurological Surgery Residency Program Director

Washington University School of Medicine 
Department of Neurological Surgery 
660 S. Euclid Avenue 
Campus Box 8057 
St. Louis, Missouri 63110

Patient Appointments: 314-362-3577 
Fax: 314-362-2107 

Clinical Interests:
Brain tumors, including glioma, astrocytoma, oligodendroglioma, glioblastoma; ependymoma, meningioma, metastatic brain tumors; neuro-oncology; neurosurgical oncology; Chiari malformation; hydrocephalus, including endoscopic third ventriculostomy; Gamma Knife radiosurgery; brain tumor immunotherapy clinical trials

Research Interests:
Dunn Research Lab

I am a faculty member in the Department of Neurological Surgery with an appointment in the Department of Pathology and Immunology at Washington University, where I am a member of the newly established interdisciplinary Center for Human Immunology and Immunotherapy Programs. I oversee a research program focused on the immunobiology of malignant glioma with the goal of translational and clinical trial efforts in the treatment of this disease. Whereas extensive genomic profiling is uncovering tumor cell vulnerabilities across many cancer types, this paradigm has not extended to glioblastoma due, at least in part, to the tremendous heterogeneity within these tumors. In contrast to conventional targeted therapeutic approaches, immune-based strategies may be particularly well-suited to treating these tumors due to the incredible diversity of antigens recognizable by immune cells. My laboratory is focused on understanding the molecular and cellular basis of the immune response to glioblastoma in preclinical and translational settings as well as clarifying the relationships between glioma genomics and immunogenicity, an area termed “cancer immunogenomics.” These investigations are complemented by ongoing clinical trial efforts in this area.

AB, Princeton University, Molecular Biology, summa cum laude
Princeton, NJ
September, 1994—June, 1998

MD, Washington University School of Medicine
St. Louis, MO

PhD, Washington University School of Medicine
St. Louis, MO
“The Interferon dependent Cancer Immunoediting Process,” completed in the laboratory of Dr. Robert D. Schreiber, Alumni Endowed Professor of Pathology, Program in Immunology, Dept. of Pathology and Immunology

Intern in General Surgery
Massachusetts General Hospital
Boston, MS

Resident in Neurological Surgery
Massachusetts General Hospital
Boston, MS
2007- 2013

Broad Institute of Harvard/MIT
Boston, MA
July 2007 – December 2007
January 2010-October 2011

Military Service:
2011-present: United States Navy Reserve Medical Corps

Hospital Appointments:
Barnes-Jewish Hospital
St. Louis Children’s Hospital

Medical Licensure:

Board Certification:
Board certified


  1. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP. Immunogenomics of Hypermutated Glioblastoma: a Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 2016 Nov;6(11):1230-1236
  2. Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP. Identification of Endogenous Neoantigen-specific CD8 T Cells in Two Murine Orthotopic Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunology Research.  2016 Oct 31
  3. Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes TM, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis, JS, Jr, Adkins DR. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial.  In press, Clinical Cancer Research.
  4. Law JM, Stark SC, Liu K, Liang NE, Hussain MM, Leiendecker M, Ito D, Verho O, Stern AM, Johnston SE, Zhang YL, Dunn GP, Shamji AF, Schreiber SL. Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. ACS Med Chem Lett. 2016 Aug 18;7(10):944-949.
  5. Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol. 2016 Oct 14. pii: S1368-8375(16)30175-0.
  6. Mei, Y, Bi WL, Du Z, Agar NYR, Laws Jr ER, Dunn GP, Santagata S, Dunn IF. Increased expression of Programmed death-ligand 1 (PD-L1) expression in human pituitary tumors. Oncotarget 2016 Sep 15.
  7. Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP. High Incidence of TERT Mutation in Brain Tumor Cell Lines. Brain Tumor Pathology. 2016 Mar 9.
  8. Bi, WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, Brewster R, Dunn GP, Al-Mefty O, Alexander BM, Santagata S, Beroukhim R, Dunn IF. Genomic Landscape of Intracranial Meningiomas. J Neurosurg. 2016 Jan 15:1-11.
  9. Dunn GP and Okada H. Principles of Immunology and its Nuances in the Central Nervous System.  Neuro-Oncology. 2015 Nov; 17 Suppl 7: vii3-vii8.  
  10. Mao DD, Gujar AD, Chen I, Mahlokozera T, Pan Y, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, Dacey RG, Tran DD, Yano H, Kim AH. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-Like Cells. Cell Reports. 2015 Jun 23; 11(11): 1809-21.
  11. Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, Kim AH, Dunn G, Simpson JR, Robinson CG. Clinical and dosimetric predictors of acute severe lymphopenia during radiotherapy and temozolomide for high-grade glioma. International Journal of Radiation Oncology, Biology, Physics. 2015 Aug 1; 92(5):1000-7
  12. Arias EJ, Dunn GP, Washington CW, Derdeyn CP, Chicoine MR, Grubb RL Jr, Moran CJ, Cross DT, Dacey, RG, Jr, Zipfel GJ. Surgical Revascularization in North American Adults with Moyamoya Phenomenon: Long Term Angiographic Follow-Up. Journal of Stroke and Cerebrovascular Diseases.  2015 May 9 pii: S1052-3057(15)00191-3.
  13. Aum D, Kim D, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. 2014. Molecular and Cellular Heterogeneity: the Hallmarks of Glioblastoma. Neurosurg Focus. 2014 Dec;37(6):E11. doi: 10.3171/2014.9.FOCUS14521.
  14. Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC. Stereotactic Laser Ablation of High-Grade Gliomas. In press, Neurosurgical Focus. Neurosurg Focus. 2014 Dec;37(6):E1. doi: 10.3171/2014.9.FOCUS14471
  15. Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC. The tyrosine kinase adaptor protein FRS2 is oncogenic and amplified in high-grade serous ovarian cancer. Mol Cancer Res.  2014 Nov 3.
  16. Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H. Emerging insights into barriers to effective brain tumor therapeutics. Front oncol. 2014 July 21; 4; 126.
  17. Campbell AA, Cunanne ME, Dunn GP, Gray ST, Lefebvre DR. Spontaneous resorption of a penetrating orbital bone fracture fragment. Ophthal Plast Reconstr Surg. 2014 May 14
  18. Dunn GP and Zada G. Publication comment on “The accuracy of predicting survival in individual patients with cancer. Congress of Neurological Surgeons Neurosurgery Watch (Tumor). Feb 3 2014.
  19. Zada G and Dunn G. Publication comment on “Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study.” Congress of Neurological Surgeons Neurosurgery Watch (Tumor). Oct 1 2013.
  20. Onken MD, Kanchi, K-L, Winkler AE, Judd NP, Law JH, Mendez E, Houck JR, LLohavanichbutr P, Schwartz SM, Chen C, Lewis JS, Dunn GP, Mardis ER, Uppaluri R. Genomic analysis identifies a mouse to human conserved genetic signature of aggressive and metastatic oral cancer. Clin Cancer Res. 2014 Jun 1;20(11):2873-84. doi: 10.1158/1078-0432.CCR-14-0205. Epub 2014 Mar 25.
  21. Yang JC, Aronson JP, Dunn GP, Codd PJ, Buchbdiner BR, Eskandar EN. Three-dimensional brain surface visualization for epilepsy surgery of focal cortical dysplasia. J Clin Neurosci. 2013 Dec 13; S0967-5868(13)00655-3
  22. Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zekster Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch MS, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC. In vivo multiplexed comprehensive interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 2.
  23. Brennan CW, Verhaak RG, McKenna A et al. and TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-77.
  24. Tu D, Zhu Z, Zhou A, Yun C, Lee K, Toms AV, Li Y, Dunn GP, Chan E, Ficarro SB, Marto JA, Jeon H, Hahn WC, Barbie DA, Eck MJ. Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1. Cell Rep 2013 Feb 27.
  25. Dunn GP, Andronesi OC, Cahill DP. From Genomics to the Clinic: Biological and Translational Insights of Mutant IDH1/2 in Glioma. Neurosurg Focus. 2013 Feb;34(2):E2
  26. Jones PS, Dunn GP, Barker II FG, Curry WT, Hochberg FH, Cahill DP. Molecular Genetics of Low-Grade Gliomas: Genomic Alterations Guiding Diagnosis and Therapeutic Intervention. 11th Annual Frye-Halloran Brain Tumor Symposium Meeting Report. Neurosurg Focus. 2013 Feb;34(2):E9
  27. Allen CT, Law J, Dunn GP, Uppaluri R. Emerging Insights into Head and Neck Cancer Metastasis. Head and Neck. 2012 Dec 22.
  28. Dunn GP, Spiliopoulos K, Plotkin S, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of Surgical Resection of Malignant Peripheral Nerve Sheath Tumors in Patients with NF1.J Neurosurg. 2012 Oct 26.
  29. Dunn GP, Ligon K, Cavenee W, Furnari F, Chin L, Depinho R, Hahn WC. Emerging Insights in the Genomic Landscape of Glioblastoma. Genes Dev. 2012 Apr 15;26(8):756-84.
  30. Dunn GP, Fecci P, Curry TW. Cancer Immunoediting in Malignant Glioma. Neurosurgery. 2012 Feb 17.
  31. Judd, NP, Sauca, OM, Winkler AE, Brotman JJ, Lewis JS, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. A mouse model of oral cancer where ERK1/2 regulates tumor aggressiveness via direct modulation of CD44. Cancer Res.  2012 Jan 1;72(1):365-74. Epub 2011 Nov 15.
  32. Dunn GP, Nahed BV, Walcott, BP, Jung H, Tierney TS, Ogilvy CS. Dual Ipsilateral Craniotomies through a Single Incision for the Treatment of Multiple Intracranial Aneurysms. World Neurosurg2011 Nov 7. [Epub ahead of print].
  33. Cotter SE, Dunn GP, Collins KM, Sahni D, Hansen JL, O’Farrell DA, Ng AK, Devlin PM, Wang LC. Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced anti-tumor immunity. Arch Dermatol. 2011 Jul;147(7):870-2.
  34. Dunn GP, Gerrard JL, Jho DH, Ogilvy CS. Surgical Treatment of a Large Distal Fusiform Anterior Cerebral Artery Aneurysm with in situ End-to-Side A3:A3 Bypass Graft and Aneurysm Trapping: Case Report and Review of the Literature. Neurosurgery2011 Feb;68(2):E587-91
  35. O’Sullivan T, Dunn GP, Schreiber RD, Bui JD. Cancer Immunoediting of the NKG2D ligand H60a. J Immunol. 2011 Oct 1;187(7):3538-45.  
  36. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. JEM 2011 Sep 26;208(10):1989-2003.
  37. Agarwalla PK, Dunn GP, Laws ER. “An Historical Context of Modern Principles in the Management of Intracranial Injury from Projectiles.” Neurosurg Focus. 2010 May;28(5):E23.
  38. Wiedemeyer RW, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn G, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L. Pattern of Rb Inactivation Dictates Response to CDK4/6 Inhibition in GBM. ProcNatlAcadSci U S A. 2010 Jun 22;107(25):11501-6. Epub 2010 Jun 7.
  39. Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008 Dec 4;8:16
  40. Refai D, Dunn GP, Santiago P. Giant cell tumor of the thoracic spine: case report and review of the literature. SurgNeurol2009 Feb;71(2):228-33; discussion 233. Epub 2008 Jan 22
  41. Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007 Aug 13; 7:12.  
  42. Dunn GP, Uppaluri R, Hessler JL, Layland MK, Derdeyn CP, Sunwoo JB. Mycoticpseudoaneurysm of the internal maxillary artery:  case report and review of the literature.  Archives of Otolaryngology—Head & Neck Surgery. 2007 133(4): 402-6.
  43. Dunn GP, Lewis J, Sunwoo, JB, Uppaluri R. Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia. Head and Neck. 2007 Jul 26; [Epub ahead of print]
  44. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: molecular and cellular mechanisms and therapeutic implications. Advances in Immunology. 2006;90:1-50.
  45. Dunn IF, Dunn G, Day AL. Neurosurgeons and their contributions to modern-day athletics: Richard C. Schneider Memorial Lecture. Neurosurgical Focus2006 Oct 15;21(4):e1.
  46. Sheehan KCFS, Lai KS, Dunn GP, Bruce AT, Carrero J, Heutel J, Arthur CD, White JM, Unanue ER, Hertzog PJ, Schreiber RD. Blocking Monoclonal Antibodies Specific for Mouse IFN-alpha/beta Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection. J Interferon Cytokine Res. 2006 Nov;26(11):804-19.
  47. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006 Nov; 6 (11):836-48.
  48. Dunn GP, Bruce AT, Sheehan KCFS, Shankaran V, Uppaluri R, Diamond MS, Arthur C, White JM, Schreiber RD. A critical role for type I interferons in the cancer immunoediting process. Nature Immunology2005 6:722-9; Comment by Smyth MJ, "Type I interferon and cancer immunoediting", in Nature Immunology2005 6:646-8
  49. Dunn GP, Ikeda H, Bruce AT, Koebel CM, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KCFS, Schreiber RD. IFN- and cancer immunoediting. Immunologic Research  2005;32(1-3):231-46
  50. Dunn GP, Sheehan KCFS, Old LJ, Schreiber RD. IFN-unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Research 2005 65:3447-53
  51. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annual Reviews of Immunology 2004 22: 329-360
  52. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 22(2): 137-148
  53. Popkin DL, Watson MA, Karaskov E, Dunn GP, Bremner R, Virgin HW IV. Murine cytomegalovirus paralyzes macrophages by blocking IFN induced promoter assembly. ProcNatlAcadSci USA2003 100(24): 14309-14
  54. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002 3(11):991-998